Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DPART Study: Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy

NCT04487145 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT04487145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04487145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DPART Study: Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy
Lead sponsor
University of California, San Francisco
Phase
Phase 4
Overall status
Completed
Start date
November 23, 2020
Completion date
April 11, 2022
Enrollment
194 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

drug-drug interaction, hiv infection